Abbott has signed a definitive agreement to acquire all of Exact Sciences’ outstanding shares for an estimated enterprise ...

Exact Sciences stock rallies as Abbott announces a $21 billion deal to acquire to the molecular diagnostics firm. Here’s why ...

We recently published 10 Stocks Jim Cramer Talked About. Abbott Laboratories (NYSE:ABT) is one of the stocks Jim Cramer ...

Abbott's $23B Exact Sciences deal adds short-term risk and earnings dilution. Click here to read what this means for ABT ...

Shares of cancer diagnostic specialist Exact Sciences (NASDAQ: EXAS) rallied 50.7% this week through Thursday at 3:30 PM EDT.

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. Shares of Exact Sciences rose sharply Thursday ...

(Reuters) -Abbott will buy cancer test maker Exact Sciences in a deal valued at up to $23 billion, including debt, marking ...

In January, Exact Sciences CEO Kevin Conroy told us that 2025 was shaping up to be a transformative year for the diagnostics ...

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and ...

Abbott announced today that it agreed to acquire diagnostics maker Exact Sciences for approximately $21 billion.

Exact Sciences, which bought Bay Area cancer testing pioneer Genomic Health in 2019, is projected to generate more than $3 ...

By bringing Exact Sciences into the fold, the expectation is that the focus on cancer diagnostics can provide a jolt to the ...